Sabine Fleischer -

The research involves developing "Topas Particle Conjugates" (TPCs) to treat CD4+ T cell-mediated diseases, involving collaborators from Helmholtz Munich and other institutions.

Sabine Fleischer is listed as a co-author on a 2025 study in Frontiers in Immunology regarding a nanoparticle platform designed to target liver sinusoidal endothelial cells (LSECs) to induce tolerance. sabine fleischer

Sabine Fleischer is a researcher associated with the University Medical Center Hamburg-Eppendorf, specializing in immunological research. specializing in immunological research.